Hims & Hers Health (HIMS) AI Stock Analysis

• Market Cap: $8.44B
• Dividend Yield: N/A
• Average Volume (3M): 29.49M
• Price to Earnings (P/E): 68.6
• Beta (1Y): 2.61
• Revenue Growth: 78.02%
• EPS Growth: 28.15%
• Country: US
• Employees: 1,637
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): 0.06
• Shares Outstanding: 219,270,890
• 10 Day Avg. Volume: 25,685,060
• 30 Day Avg. Volume: 29,487,857
• PEG Ratio: -0.07
• Price to Book (P/B): 10.95
• Price to Sales (P/S): 3.54
• P/FCF Ratio: 26.33
• Enterprise Value/Market Cap: 1.73
• Enterprise Value/Revenue: 6.60
• Enterprise Value/Gross Profit: 8.80
• Enterprise Value/Ebitda: 92.41
• 1Y Price Target: $46.25
• Price Target Upside: 24.70% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 11
• EPS Forecast (FY): 0.48
• Revenue Forecast (FY): $2.35B

• Rating: 67 Neutral
• Price Target: $39.00 ▲(5.15% Upside)

Hims & Hers Health's overall stock score is driven by strong financial performance and positive earnings call guidance. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The company's high leverage and increased G&A costs pose additional risks.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust market demand and effective business strategies, supporting long-term financial health and expansion potential.

International Expansion

International expansion through acquisitions enhances market reach and diversification, providing a foundation for sustained growth and competitive advantage.

Technological Advancements

Investing in technology and leadership strengthens the company's platform, improving service delivery and positioning it for future innovation and efficiency.

Negative Factors

High Leverage

Significant leverage can increase financial risk and limit flexibility, potentially impacting the company's ability to invest in growth opportunities.

Increased Costs

Rising costs, particularly in G&A, can pressure margins and reduce profitability, challenging the company's ability to maintain cost efficiency.

GLP-1 Subscriber Decline

Subscriber decline in key segments can affect revenue stability and growth, necessitating strategic adjustments to retain and attract customers.

Hims & Hers Health Business Overview & Revenue Model

Company Description

Hims & Hers Health (HIMS) is a telehealth company focused on providing accessible healthcare solutions primarily for men and women. Founded in 2017, the company operates in the digital health sector, offering a range of products and services including prescription medications for conditions such as erectile dysfunction, hair loss, and skincare, as well as wellness products like vitamins and supplements. HIMS leverages a direct-to-consumer model, utilizing an online platform that allows customers to consult with licensed healthcare professionals and receive treatment through a convenient digital experience.

How the Company Makes Money

Hims & Hers Health generates revenue through multiple streams, primarily by selling prescription medications and health-related products directly to consumers. The company operates on a subscription-based model for certain products, which provides recurring revenue. Additionally, HIMS earns income from telehealth consultations, where customers pay for access to healthcare providers. Strategic partnerships with pharmacies and healthcare networks also contribute to its revenue, enabling HIMS to efficiently distribute its products. The company's focus on branding and marketing enhances customer acquisition, further driving sales and profitability.

Hims & Hers Health Financial Statement Overview

Summary

Hims & Hers Health shows strong revenue and profit growth with a healthy gross profit margin and improved net profit margin. However, the high debt-to-equity ratio indicates significant leverage, posing a potential risk.

Income Statement

Hims & Hers Health has demonstrated strong revenue growth with a TTM revenue increase of 9.81%. The company has maintained a healthy gross profit margin of 76.20% and improved its net profit margin to 9.62% in the TTM period. EBIT and EBITDA margins have also shown positive trends, indicating improved operational efficiency. However, the gross profit margin has slightly decreased compared to the previous year.

Balance Sheet

The company has a high debt-to-equity ratio of 1.86 in the TTM period, indicating significant leverage. However, the return on equity has improved to 38.17%, showcasing effective use of equity to generate profits. The equity ratio stands at 26.00%, reflecting a moderate level of financial stability.

Cash Flow

Hims & Hers Health has shown a positive free cash flow growth rate of 10.07% in the TTM period, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.96, suggesting efficient conversion of income into cash. However, the free cash flow to net income ratio of 0.46 indicates room for improvement in cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.21B	1.48B	872.00M	526.92M	271.88M	148.76M
Gross Profit	1.66B	1.17B	714.95M	408.72M	204.49M	109.45M
EBITDA	157.91M	78.99M	-19.94M	-61.22M	-110.97M	-14.09M
Net Income	133.79M	126.04M	-23.55M	-65.68M	-107.66M	-18.11M
Balance Sheet
Total Assets	2.23B	707.54M	441.19M	366.34M	420.58M	118.70M
Cash, Cash Equivalents and Short-Term Investments	629.74M	300.25M	220.98M	179.63M	247.27M	100.21M
Total Debt	1.12B	11.35M	9.95M	5.31M	5.48M	0.00
Total Liabilities	1.65B	230.82M	97.16M	54.60M	85.97M	265.57M
Stockholders Equity	580.98M	476.72M	344.03M	311.74M	334.62M	-146.87M
Cash Flow
Free Cash Flow	131.54M	198.33M	46.99M	-33.78M	-39.42M	-6.71M
Operating Cash Flow	325.08M	251.08M	73.48M	-26.53M	-34.41M	-2.48M
Investing Cash Flow	-958.49M	-19.05M	-12.11M	34.70M	-156.27M	-39.70M
Financing Cash Flow	813.49M	-107.84M	-11.47M	-33.13M	235.04M	47.74M

Hims & Hers Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 37.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Negative. The current price of 37.09 is below the 20-day moving average (MA) of 39.26, below the 50-day MA of 48.26, and below the 200-day MA of 46.70, indicating a bearish trend. The MACD of -3.30 indicates Negative momentum. The RSI at 42.82 is Neutral, neither overbought nor oversold. The STOCH value of 76.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIMS.

Hims & Hers Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DOCS	72 Outperform	$9.62B	40.74	24.61%	―	20.21%	44.14%
HIMS	67 Neutral	$8.44B	68.57	26.21%	―	78.02%	28.15%
GDRX	65 Neutral	$960.60M	32.95	4.90%	―	1.30%	―
EPC	63 Neutral	$815.45M	32.89	1.62%	3.26%	-1.34%	-73.59%
NUS	61 Neutral	$493.35M	4.65	14.55%	2.63%	-12.10%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TDOC	47 Neutral	$1.32B	―	-15.42%	―	-2.37%	77.85%

Hims & Hers Health Corporate Events

Hims & Hers Health, Inc. Reports Strong Growth and Strategic Optimism

The recent earnings call for Hims & Hers Health, Inc. paints a picture of robust growth and strategic optimism, despite some operational challenges. The company reported significant revenue growth and is actively pursuing strategic partnerships and international expansion. However, challenges such as declining gross margins and increased general and administrative costs were also highlighted. Overall, the sentiment remains positive with a strong outlook for the future.

Hims & Hers Health Reports Strong Q3 2025 Growth

Hims & Hers Health, Inc. is a leading health and wellness platform that offers personalized care solutions to enhance the well-being of individuals globally. The company operates primarily in the health and wellness sector, providing accessible healthcare services through its innovative online platform.

Hims & Hers Health Announces COO Transition

On September 28, 2025, Hims & Hers Health, Inc. announced that its Chief Operating Officer, Nader Kabbani, will transition to an advisory role effective November 2, 2025, providing strategic guidance until July 2026. Mike Chi, currently the Chief Commercial Officer, will assume the role of Chief Operating Officer, consolidating operations, marketing, product, and commercial functions. Chi, who joined the company in April 2021, brings over 20 years of experience in consumer internet and has previously held senior marketing roles at Zola, INTERMIX, and Gilt Groupe. The company’s Compensation Committee will review Chi’s compensation in light of his new responsibilities.

The most recent analyst rating on (HIMS) stock is a Sell with a $28.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.

Hims & Hers Health Expands Information Dissemination Strategy

Hims & Hers Health, Inc. has announced that it will disseminate information about its operations, products, and services through various public channels, including its websites, social media accounts, and press releases. This approach aims to ensure broad and inclusive distribution of material information to the public, potentially impacting how stakeholders access updates about the company’s activities.

The most recent analyst rating on (HIMS) stock is a Sell with a $30.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.

Hims & Hers Health Expands with New Ohio Facility

On September 1, 2025, Hims, Inc., a subsidiary of Hims & Hers Health, Inc., signed a lease agreement for a 352,012 square foot facility in New Albany, Ohio, intended for office, research, development, laboratory, manufacturing, and pharmaceutical dispensing purposes. The 15-year lease, with options for extension, includes an annual base rent starting at $5,984,204, subject to annual increases and initial abatements. This move signifies a strategic expansion for Hims & Hers Health, potentially enhancing its operational capacity and market presence.

The most recent analyst rating on (HIMS) stock is a Hold with a $53.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.